Research & Development
Alzheimer's: Page 2
C2N Diagnostics study demonstrates clinical utility of Alzheimer's disease blood test
The firm said its current PrecivityAD blood test is bolstered by new research that found the test provided clinically informative results in approximately 85% of cases.
December 12, 2022
Roche nabs FDA clearance for two Alzheimer's disease CSF assays
The assays measure beta Amyloid (1-42) and Phospho Tau (181P) concentrations in cerebrospinal fluid samples from adults age 55 and older.
December 8, 2022
Blood test in study detects proteins fundamental to dementia before symptoms develop
The research team is working with scientists at AltPep, a University of Washington spinout company, to develop a soluble oligomer binding assay as a diagnostic test.
December 5, 2022
Diadem presents data at CTAD on blood test for early prediction of Alzheimer's
The firm is preparing to launch a test next year that enables drug developers to identify with high confidence individuals who will experience a decline to Alzheimer's dementia up to six years in advance of diagnosis.
December 5, 2022
C2N Diagnostics launching next-generation blood test for Alzheimer's disease detection
With an anticipated launch in the first quarter of 2023, the PrecivityAD2 blood test would facilitate earlier diagnosis of Alzheimer's disease pathology than is possible with current tests, the firm said.
November 29, 2022
Urine biomarker may reveal early-stage Alzheimer’s disease, study shows
A urine-based test for early Alzheimer’s detection would be inexpensive, noninvasive, widely accessible, and considerably easier to deploy in routine screening than current methods.
November 30, 2022
Quest launches long-COVID testing panels for consumers
Ohio, Kentucky doctors convicted in scheme to bill Medicaid for millions of dollars in unnecessary urinalysis testing
RNA-seq analysis links protein to spread of pancreatic cancer, reveals potential drug target
Patients prefer immediate test results, even when the news is bad
Point-of-care test developer Proxim Diagnostics obtains strategic investment from BioMérieux
Quest Diagnostics offers suite of services for transplant patients and living donors
Blood-based MDx test developer DiamiR to present poster on trial findings at CTAD
The poster will be presented during the session “Clinical trials: Biomarkers including plasma” during the 15th Clinical Trials on Alzheimer’s Disease (CTAD) in San Francisco from November 29 to December 2.
November 28, 2022
Alzheimer’s study compares blood-based biomarkers, other detection technologies
The Global Alzheimer’s Platform Foundation technology study, with more than 1,000 participants, focuses on access and diversity.
November 15, 2022
NanoMosaic obtains rights to biomarker test for the diagnosis, prognosis of anesthesia-induced delirium, Alzheimer's
The test uses the Tessie system to alleviate bottlenecks in proteomics analysis and to enable protein interrogation as well as multiomics analysis within a single chip during one run.
October 12, 2022
Diadem nabs $2.5M to further validate Alzheimer’s blood test
The two-year grant will enable Diadem, a company that has been developing a blood-based test for the early prediction of Alzheimer's disease (AD), to leverage data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), a longitudinal multicenter study designed to enable development of biomarkers for the early detection and tracking of AD.
September 6, 2022
Roche nabs FDA breakthrough designation for Alzheimer’s Dx
The panel, a blood-based biomarker test, is intended to be used in conjunction with other clinical information in symptomatic patients who are being evaluated for Alzheimer's disease and other causes of cognitive decline.
July 18, 2022
Alzheimer’s test developer Diadem joins DPUK
Diadem's AlzoSure Predict blood test identifies signs of cognitive impairment that will or will not progress to Alzheimer's dementia up to six years before diagnosis.
June 12, 2022
Page 2 of 6